CVS Health stock rises 1.48 percent as Evercore sets USD 125.00 target

Published on 10/03/2026 at 21:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock posted USD 2.58 adjusted EPS in Q2 2026, up 42.5 percent year over year. Management lifted adjusted 2026 guidance to USD 7.90-8.10.

Extreme Nahaufnahme bunter pharmazeutischer Kapseln und Tabletten mit Bokeh-Hintergrund — CVS Health Corp. Makroaufnahme zeigt bunte Pharmakapseln und Tabletten in Detailansicht, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) stock was last at USD 86.46 on the NYSE on October 2, 2026 at 4:00 p.m. ET, up 1.48 percent for the session. According to Markets Insider on October 2, 2026, Evercore ISI maintained a Buy rating and set a USD 125.00 price target.

Evercore keeps its Buy rating

The target stands USD 38.54 above the latest price, equivalent to 44.6 percent upside from USD 86.46. The analyst call follows CVS Health's second-quarter operating improvement and keeps attention on whether earnings gains can continue.

Markets Insider also reported quarterly revenue of USD 106.1 billion and net profit of USD 3.0 billion for the quarter ended June 30, 2026. Revenue rose from USD 98.92 billion in the year-ago quarter, while net profit increased from USD 1.02 billion.

Adjusted EPS rises 42.5 percent

According to Yahoo Finance on September 4, 2026, CVS Health reported adjusted EPS of USD 2.58 in Q2 2026, up 42.5 percent year over year and 37.97 percent above the Zacks consensus estimate. Revenue increased 7.3 percent to USD 106.10 billion.

The same report said management raised adjusted full-year 2026 EPS guidance to USD 7.90-8.10 from USD 7.30-7.50. Full-year revenue guidance increased to at least USD 414 billion from at least USD 405 billion, while operating cash flow guidance rose to at least USD 11.5 billion from at least USD 9.5 billion.

Stock remains below its yearly high

CVS Health stock carried a market capitalization of USD 110.3 billion and volume of 10,446,777 shares on October 2, 2026. At USD 86.46, the stock stood 21.9 percent below its 52-week high of USD 110.68, while the 52-week low was USD 69.51.

For investors, the central calculation is straightforward: the latest quarter delivered faster earnings growth than revenue growth, but the share price remains materially below its yearly peak. The USD 125.00 Evercore target therefore places valuation and execution at the center of the current debate.